Merck

April 20, 2018April 20, 2018

SD-101 and Keytruda Combo Fights Head and Neck Tumors, Trial Shows

News

A combination of Dynavax Technologies’ immunotherapy SD-101 and Keytruda triggered tumor-fighting responses in a third of patients with an advanced head and neck cancer, a Phase 1b/2 clinical trial showed. The response rate was double the 15 ... Read more

April 16, 2018April 16, 2018

First Stage of Bemcentinib-Keytruda Phase 2 Trial for Lung Cancer Completes Patient Enrollment

News

The first part of a Phase 2 trial investigating the AXL inhibitor bemcentinib in combination with Keytruda (pembrolizumab) in advanced non-small cell lung cancer (NSCLC) patients has completed enrollment of the planned ... Read more

April 13, 2018April 13, 2018

Keytruda Beats Chemo at Increasing NSCLC Patients’ Survival, Phase 3 Trial Shows

News

Non-small cell lung cancer (NSCLC) patients with PD-L1 protein in their tumors lived significantly longer when treated with the immunotherapy Keytruda (pembrolizumab) than standard platinum-based chemotherapy, a Phase 3 clinical ... Read more

April 11, 2018April 11, 2018

Keytruda-Epacadostat Combo Fails Primary Goal in Phase 3 Trial for Melanoma, Companies Announce

News

A Phase 3 clinical trial evaluating a combination of Keytruda and epacadostat in metastatic melanoma patients will be stopped after the combo failed the study’s first primary goal, Incyte Corporation and Merck announced. ... Read more

March 19, 2018March 19, 2018

Clinical Trial of Vaccine, IO102, Plus Keytruda in Advanced NSCLC Patients Planned

News

IO Biotech and Merck & Co recently signed an agreement to assess IO Biotech’s lead candidate IO102, an anti-cancer vaccine, in combination with Keytruda (pembrolizumab) in patients with metastatic non-small ... Read more

March 16, 2018March 16, 2018

FDA Grants Priority Review to Keytruda for Advanced Cervical Cancer

News

The U.S. Food and Drug Administration will be giving priority review to Merck’s Keytruda (pembrolizumab) as a treatment for women whose advanced cervical cancer progressed during or after chemotherapy. Priority ... Read more

March 7, 2018March 7, 2018

Britain’s NICE Recommends That Bavencio Be Covered for Merkel Cell Carcinoma

News

Britain’s National Institute for Health and Care Excellence (NICE) has recommended that the National Health Service cover Bavencio (avelumab) as a treatment for adults with metastatic Merkel cell carcinoma (mMCC), a ... Read more

February 14, 2018February 14, 2018

Phase 2 Trial to Evaluate Combo of Imprime PGG, Keytruda in Head and Neck Cancer

News

Biothera Pharmaceuticals has begun treating patients in a Phase 2 clinical trial evaluating its Imprime PGG in combination with Merck’s Keytruda (pembrolizumab) for patients with advanced squamous cell carcinoma ... Read more

January 23, 2018January 23, 2018

Keytruda Slows Liver Cancer Progression in Phase 2 Trial

News

A study of Keytruda (pembrolizumab) in patients with a difficult-to-treat type of liver cancer suggests that the treatment may extend the time before their disease progresses. Data presented at ... Read more

January 22, 2018

Rare Melanoma Responds Well to Immunotherapy Despite Thoughts It Wouldn’t, Study Reports

News

A rare type of malignant melanoma is treatable with immunotherapies, according to a new study — overturning previous beliefs that the cancer, called desmoplastic melanoma, is not treatable with such ... Read more

Pin It on Pinterest